Skip Navigation

Faculty Directory

Subhra Chakraborty, PhD

  • Assistant Scientist

Departmental Affiliations

Contact Information

615 N. Wolfe Street
Room E5534
Baltimore, Maryland 21205

410-502-2510

SciVal Research Profile

View Current Courses

Education

MPH, Johns Hopkins Bloomberg School of Public Health, 2013
PhD, University of Jadavpur, 2004
MSc, University of Burdwan, 1997

Overview

My research is focused on strategies to reduce the morbidity and mortality due to diarrhea. Accordingly, my research is focused in three areas, delineating the role of the environment and understanding the occurrence and transmission of diarrheal pathogens, develop new diagnostic tools for resource poor settings to better understand disease epidemiology and finding new strategies for improved enteric vaccines. Below are short descriptions of specific research projects.

Immune Responses to enteric vaccines: I am working on to understand the systemic and mucosal immune responses to different candidate enteric vaccines, including ETEC and Shigella. The key objective of these work are to find biomarkers for protective immunity using immunoproteome microarray and ELISA, role of memory B cell and T cell in the protective efficacy of a vaccine. My studies also involves developing and evaluating new assays to better understand the immune responses.

Evaluating candidate enteric vaccines in humans: I am involved in evaluation of safety, immunogenicity and efficacy of different candidate enteric vaccines (ACE527 ETEC Vaccine, Fimbrial Tip Adhesin (CfaE) + LTR192G ETEC vaccine, Bioconjugate vaccine against Shigella flexneri 2a, Assessing Rifaximin in preventing campylobacteriosis etc). With collaborators I have developed an experimental challenge model of ETEC in humans. This model facilitates initial evaluation of vaccines thus avoiding the huge expenses and limitations of the efficacy evaluation in the field.

Gut microbiome and diseases: My project is focused on the longitudinal changes in gut microbiome after experimental infection with virulent ETEC and after antibiotic treatment. We found a predictive gut flora for being susceptible and resistant to clinical diarrhea. I am now performing similar but in depth studies in ETEC and other bacteria in field studies.

Epidemiology and transmission of diarrhea:

a) Developing Diagnostics for infectious diseases suitable for resource poor settings.

b) Diarrhea surveillance in Bangladesh, India and Africa.

c) Role of environment in seasonal epidemiology of diarrhea.

Role of Zinc as antimicrobial and physiological therapeutics against diarrhea: World Health Organization guidelines recommend antibiotic treatment for clinical dysentery. However, Shigella frequently acquires resistance to antibiotics that were previously effective in reducing disease severity and duration along with pathogen excretion. In this project we are studying to understand the molecular mechanisms of the effect of Zn in inflammatory diarrhea to successfully use Zn in reducing the disease.

Honors and Awards

Women’s Career Development Grant, American Society for Microbiology (ASM), 2008. 

UNESCO-MIRCEN fellowship for the year 2000-2001.

Postdoctoral fellowships, Dept of Infectious disease, School of Medicine, Washington University of St. Louis. 2004-2006

Postdoctoral fellowship, Dept of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University. 2006-2008.

  • Diarrhea
  • Enteric disease
  • Clinical trial
  • Enterotoxigenic E. coli
  • Shigella
  • Cholera
  • Francisella tularensis
  • tularemia
  • Entamoeba histolytica
  • antimicrobial resistance.

Most recent publications

  • Chakraborty S*, Harro C, DeNearing B, Bauers N, Dally L, Flores J, Van de Verg L, Sack DA, Walker R. Evaluation of the Safety, Tolerability and Immunogenicity of an Oral, Inactivated Whole Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects. Clin Vaccine Immunol. 2016, 23(4):315-25.
  • Pop M, Paulson JN, Chakraborty S (Co first author), Astrovskaya I, Lindsay BR, Li S, Bravo HC, Harro C, Parkhill J, Walker AW, Walker RI, Sack DA, Stine OC. Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment. BMC Genomics. 2016, 17(1):440.
  • Chakraborty S*, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA. Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407. Clin Vaccine Immunol. 2015 Nov 23(1):55-64.
  • Lindsay BR, Chakraborty S (Co first author), Harro C, Li S, Nataro JP, Sommerfelt H, Sack DA, Colin Stine O. Quantitative PCR and culture evaluation for Enterotoxigenic E. coli (ETEC) associated diarrhea in volunteers. FEMS Microbiol Lett. 2014, 352(1):25-31.
  • Kazi M, Sarkar P, Sheik I, Chakraborty S. Zinc recovers altered intestinial ion-transport and barrier function caused by Shigella infection in T84 cells. FASEB J. 2014, 28(1):902.9